FDA OKs Adherium’s smart sensors to boost adherence to AstraZeneca’s inhalers
15 Apr 2024
On Monday, the FDA cleared the use of Adherium's Hailie Smartinhaler platform with AstraZeneca's asthma and chronic obstructive pulmonary disease (COPD) inhalers to enhance patient monitoring and enable personalised treatments. The nod follows a move from the pharma last month to cap out-of-pocket costs for its inhalers in response to a US Senate investigation into the high cost of inhaled respiratory medicines compared with other countries.
Specifically, Adherium’s smart sensors can be applied to asthma rescue medication Airsupra (albuterol/budesonide) and COPD treatment Breztri (budesonide/glycopyrrolate/formoterol fumarate). According to the Australian company, Hailie's compatibility with Breztri gives it 100% coverage for triple therapy inhalers in the US.
Adherium's cloud-based platform uses Bluetooth-enabled sensors that attach to patient inhalers to collect medication use data, with real-time feedback delivered to patients via the Hailie app and to physicians through the Hailie portal. This personalised approach is expected to bolster overall treatment efficacy and significantly improve patient outcomes.
The company highlighted that independent studies have shown Hailie to increase adherence to preventative medication by 180% in children and 59% in adults, while also reducing severe exacerbations in adults by 61%.
CEO Paul Mastoridis called Hailie "a powerful tool in the fight against chronic respiratory diseases," noting "this is just the beginning of our journey to transform respiratory care."
Last year, FirstWord interviewed several US and European key opinion leaders (KOL) in respiratory health to explore their perspectives on digital inhalers. While the majority acknowledged that the devices provide a true, objective measure of medication adherence, they emphasised cost as a significant barrier hindering their adoption. They advocate for adopting a 'carrot-and-stick' approach to incentivise their use, while also striving to make the costs more manageable. For more, see KOL Views: Digital inhalers good for compliance - but bad for the wallet.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.